IRIS
BALBI, MATILDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.691
AS - Asia 22
NA - Nord America 8
SA - Sud America 2
Totale 2.723
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.691
CN - Cina 21
US - Stati Uniti d'America 8
BR - Brasile 2
SG - Singapore 1
Totale 2.723
Salva come PNG Salva come JPEG
Città #
Genoa 1.587
Genova 532
Vado Ligure 364
Rapallo 196
Beijing 13
Bordighera 12
Boston 6
Ashburn 2
Singapore 1
São Paulo 1
Três Barras do Paraná 1
Totale 2.715
Salva come PNG Salva come JPEG
Nome #
Presynaptic GLP-1 receptors enhance the depolarization-evoked release of Glutamate and GABA in the mouse cortex and hippocampus 192
Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease. 184
Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression 147
Group I metabotropic glutamatergic receptors regulating glutamate release and microglia phenotype in a murine model of amyotrophic lateral sclerosis 127
In-vivo therapeutic effects of extracellular vesicles derived from mesenchymal stem after systemic administration on ALS mice 100
GEBR-32A, A NEW PROMISING PDE4D INHIBITOR FOR TREATMENT OF ALZHEIMER'S DISEASE 98
Glucagon Like Peptide-1 increases glutamate release in the mouse cerebral cortex and hippocampus by activacting presynaptic GLP-1R 92
Changes at glutamate tripartite synapses in the prefrontal cortex of a new animal model of resilience/vulnerability to acute stress 92
In-vitro and in-vivo studies depict metabotropic glutamate receptor 5 as a potential pharmacological target to modulate disease progression in ALS 87
The complex phenotype and function of spinal cord microglia during ALS progression and the impact of metabotropic glutamate receptor type 5 down-regulation in SOD1G93A mice 86
Blocking glutamate mGlu5 receptors with the negative allosteric modulator CTEP improves disease course in SOD1G93A mouse model of amyotrophic lateral sclerosis 83
Genetic Downregulation of the Metabotropic Glutamate Receptor Type 5 Dampens the Reactive and Neurotoxic Phenotype of Adult ALS Astrocytes 82
Reducing mglur5 expression attenuates the reactive phenotype of astrocytes cultured from the spinal cord of late symptomatic SOD1G93A mice 82
Nearly 30 years of animal models to study amyotrophic lateral sclerosis: A historical overview and future perspectives. 80
cGMP MODULATES LONG-TERM POTENTIATION AND MEMORY BY ENHANCING ABETA PRODUCTION 76
In-vivo and in-vitro evidence supporting the role of mGlu5 receptor as a key regulator of glutamate downstream effects in ALS 72
Genetic and pharmacological effects by blocking mGlu5 receptor in the SOD1G93A mouse model of amyotrophic lateral sclerosis 67
Preclinical study showing a gender specific protective properties of conjugated linoleic acid (CLA) for amyotrophic lateral sclerosis 65
Phenotype changes of microglia in SOD1G93A mice after mGluR5 genetic down regulation 59
The Physio-Pathological Role of Group I Metabotropic Glutamate Receptors Expressed by Microglia in Health and Disease with a Focus on Amyotrophic Lateral Sclerosis 58
PRESYNAPTIC GLP-1 RECEPTORS ENHANCE GLUTAMATE AND GABA RELEASE FROM PURIFIED MOUSE CORTICAL AND HIPPOCAMPAL SYNAPTOSOMES 57
Multiple approaches reveal altered lipid metabolism, neurotransmitter release and nervous conduction in a zebrafish model of Alexander Disease 52
Therapeutic effect of extracellular vesicles derived from mesenchymal stem cells in amyotrophic lateral sclerosis 51
Partial deletion of mGluR5 affects M1 and M2 phenotypes in microglia acutely isolated from SOD1(G93A) mice during disease progression 51
microRNAs shuttled by extracellular vesicles derived from mesenchymal stem cells rescue glial activation in in-vitro models of amyotrophic lateral sclerosis 50
In-vitro and in-vivo evidence supporting the therapeutic effect of extracellular vesicles derived from mesenchymal stem cells in amyotrophic lateral sclerosis 50
Combined motor and behavioural tracking approach to stratify ALS progression in SOD1(G93A) mice. 46
Partial deletion of mGluR5 affects microglia inflammatory phenotype, bioenergetic characteristics, and red-ox state during ALS progression in SOD1G93A mice 42
Sex-specific motor and behavioural parameters for early stratification of ALS progression in SOD1(G93A) mice. 40
In-vitro and in-vivo studies showing the beneficial effects of extracellular vesicles derived from mesenchymal stem cells on the reactive astrocyte activation in amyotrophic lateral sclerosis 40
The mGlu5 receptor negative allosteric modulator CTEP as a pharmacological tool to dampen ALS disease progression: in-vivo preclinical studies and clinical perspectives 38
Changes of the microglia phenotype in the SOD1G93A mouse model of amyotrophic lateral sclerosis after mGluR5 genetic down-regulation 38
The partial deletion of mGluR5 affects the pro- and anti-inflammatory and bioenergetic characteristics of microglia during ALS progression in SOD1(G93A) mice 38
In-vitro and in-vivo evidence supporting the therapeutic effect of extracellular vesicles derived from mesenchymal stem cells in amyotrophic lateral sclerosis 38
MSC-derived extracellular vesicles for the treatment of ALS 34
Synapto-gliosomal characterization in a zebrafish model of Alexander disease 33
microRNAs shuttled by extracellular vesicles derived from mesenchymal stem cells revert glial activation and neurotoxicity in in-vitro models of amyotrophic lateral sclerosis 30
Molecular signatures of astrocytes and microglia maladaptive responses to acute stress are rescued by a single administration of ketamine in a rodent model of PTSD 30
Preventive effects of conjugated linoleic acid (CLA) in-vivo oral treatment in the SOD1G93A preclinical model of amyotrophic lateral sclerosis 30
Phenotype changes of spinal cord microglia cells acutely purified from SOD1G93AALS mice during disease progression: focus on the genetic down regulation of mGlu5 receptor 29
Therapeutic effects of MSC-derived EVs intranasally administered on ALS mice 19
Efficacy and Safety of Visible and Near-Infrared Photobiomodulation Therapy on Astenospermic Human Sperm: Wavelength-Dependent Regulation of Nitric Oxide Levels and Mitochondrial Energetics 18
Chromosomal Deletion Involving ANKRD26 Leads to Expression of a Fusion Protein Responsible for ANKRD26-Related Thrombocytopenia 15
Intranasal in-vivo administration of MSC-derived EVs on ALS mice 15
miR-29a-3p and TGF-β Axis in Fanconi anemia: mechanisms driving metabolic dysfunction and genome stability 13
null 1
null 1
Totale 2.828
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.674
article - articoli 4.144
book - libri 0
conference - conferenze 6.189
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202186 0 0 0 3 2 15 11 7 6 26 11 5
2021/2022182 1 8 13 11 7 10 23 37 17 16 17 22
2022/2023245 24 20 7 19 21 28 2 22 50 6 44 2
2023/2024301 6 23 23 32 29 48 19 18 4 20 28 51
2024/20251.045 56 47 24 80 105 93 107 183 33 68 109 140
2025/2026649 246 79 171 153 0 0 0 0 0 0 0 0
Totale 2.828